MS-Related Disability Worsening and Thalamic Volume Loss

计划入组 2,400 人 · 首次发布于 2026 年 8 月 10 日

Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)

计划入组 259 人 · 首次发布于 2017 年 3 月 8 日

COVID-19 and Multiple Sclerosis Disease Modifying Therapies

计划入组 14,240 人 · 首次发布于 2021 年 4 月 28 日

Immune Modifying Particles

Cardiovascular disease therapies (Sagene Pharmaceuticals)

tolerizing immune modifying nanoparticles

NeuroBo Pharmaceuticals

United States

OS Therapies

United States

Biorestorative Therapies

United States

Advances in Alzheimer's Disease Treatment: A Focus on Disease-Modifying Therapies

Scripta Therapeutics Raises $12M to Target Transcription Factors for Disease-Modifying Therapies

ATTR-CM Treatment Landscape Expands with Three FDA-Approved Disease-Modifying Therapies